Search

LONDON, ON – Hospital researchers from Lawson Health Research Institute have published a recent study that assessed the use of a specialized treatment for chronic pain and its impact on health care use and opioid prescribing.   

Paravertebral blocks (PVBs) belong to a broader group of procedures called “nerve blocks.” A recent Toronto Star report noted that OHIP has been billed $420 million for nerve block procedures since 2011. PVBs involve injecting medication around the nerves where they exit the bones of the spine, at different locations depending on the patient and the chronic pain they are experiencing.  

The regular use of these procedures has been questioned by health care providers due to the high cost and limited evidence of their benefit in reducing chronic pain. While the effectiveness of PVBs has been examined in trauma, cancer pain and regional anesthesia during surgery, they have not been evaluated for use in chronic pain despite widespread use in Ontario.  

It is estimated that one in five Canadians live with chronic pain. Pain that persists can affect all aspects of someone’s life and health, particularly when it is not being managed.  

This new study from London researchers found that 66,310 patients had a PVB between July 2013 and March 2018, and 47,723 patients were included in the study. In the year after a patient’s first PVB, there was a significant increase in the number of physician visits. Additional PVBs were frequently performed after the first treatment, with over 26 per cent of patients receiving a PVB ten or more times in one year, with almost eight per cent of patients receiving 30 or more. No overall change was found in opioid dosage in the year after PVB was initiated compared to the year before. 

“Frequent use of PVB is common. Initiating treatment with PVCs is associated with marked increases in health care utilization, which includes physician visits and other injection procedures,” explains Dr. Eldon Loh, Lawson Associate Scientist and Physiatrist at St. Joseph’s Health Care London. 

This research provides a broad perspective on the use of PVBs in Ontario, and on the use of nerve blocking treatments in general. There has been a concern for several years about the over use of these procedures; however, this is the first study to systematically document the impact on health care utilization and opioid use. 

"We hope that from this study, the appropriate use of PVBs and other pain interventions will be re-evaluated at a provincial level to ensure the use of health resources is being properly managed and we achieve the best outcome for patients,” Dr. Loh adds. 

The study, “A Retrospective Cohort Study of Healthcare Utilization Associated with Paravertebral Blocks for Chronic Pain Management in Ontario,” is published in the Canadian Journal of Pain. 

-30- 

See all Lawson Media Releases

LONDON, ON – Published in the Journal of Cellular and Molecular Medicine, a team at Lawson Health Research Institute have discovered unique patterns of blood plasma proteins in critically ill patients that may help develop a more personalized approach to treating severe COVID-19.

Called the plasma proteome, the proteins being studied are released by cells that often play an important role in the body’s immune response to viruses. The research team studied how they adapt and change to a COVID-19 infection. 

As part of the study, blood samples were taken from 30 subjects in three patient groups at London Health Sciences Centre (LHSC). One group had patients with COVID-19, another group had patients with severe infection but were negative for COVID-19, and the third was a healthy control group. Blood samples were drawn on the day of critical care admission and again on days three, seven and ten in hospital. 

“We collected plasma from these patients and measured well over a thousand proteins with great accuracy using new technology that combines immunology and genomics,” says Dr. Douglas Fraser, Lawson Scientist, Critical Care Physician at Children’s Hospital at LHSC and Professor at Western University’s Schulich School of Medicine & Dentistry. “With the use of this advanced technology, we were able to better analyze the protein patterns and better understand what is happening with COVID-19, especially in critically ill patients.”

The research team found that COVID-19 patients demonstrated changes in immunosuppression pathways, which typically keeps the immune system balanced. In critically ill patients, the changes were heightened. Analyses of the plasma proteome helped researchers determine which cells in the body are active during the disease state and which signaling pathways were activated.

"In-depth analysis of the human plasma proteome helps us capture tissue proteins that can provide us with information regarding organ integrity during infection," says Dr. Cristiana Iosef, Lawson Research Associate PhD. “This is important because it will allow us to search for new blood biomarkers that are specific for COVID-19 patients.”

This research, which used state-of the-art analysis technology, was enabled by existing expertise and technologies through Children’s Health Research Institute (CHRI), a program of Lawson. 

“This study has allowed us to understand the progression of the disease processes in very sick patients, providing us clues on the body’s immune system and other systems that were reacting to the severe disease,” says Dr. Victor Han, Lawson Scientist, Director of CHRI and Professor at Schulich Medicine & Dentistry. “We hope that this knowledge will allow us to identify the patients who will become severely ill and develop new therapies to counteract the changes occurring within their bodies.”

Dr. Fraser, who is also a scientist at CHRI, adds that the team can now examine potential new drug therapies with the hopes of improving outcomes for these patients. 

The next steps for the research team will be to use this technology to examine plasma biomarkers in long COVID patients to determine why some develop prolonged disease after a COVID-19 infection.
 

Scientists at Children’s Health Research Institute (a program of Lawson Health Research Institute), Sunnybrook Research Institute and The Hospital for Sick Children (SickKids) are working together to study the potential benefits of inhaled sedation as an alternative to keep critically ill children sedated and comfortable.

“Many sick children need support from a ventilator and other life-saving treatments, and may require intravenous (IV) sedatives to tolerate these uncomfortable therapies,” says Dr. Rishi Ganesan, Lawson Associate Scientist and Paediatric Neurocritical Care Physician at Children’s Hospital at London Health Sciences Centre (LHSC). “However, our current sedation options may contribute to a complication called delirium. We are interested in evaluating if delirium and long-term neurological complications are lower in children receiving inhaled sedation compared to those receiving IV sedation, which is the current standard of care.” 

Delirium is an acute change in mental state that children in critical care can sometimes develop as a result of their critical illness and the medications and therapies they receive during their hospital stay. Delirium presents as confusion, disorientation, agitation, excessive drowsiness or poor attention. Dr. Marat Slessarev, Lawson Scientist and Critical Care Physician at LHSC, has been researching and comparing inhaled sedation to IV sedation in adults since the pandemic hit in 2020 in a collaborative trial called SAVE-ICU with Dr. Angela Jerath, Anesthesiologist and Scientist at Sunnybrook.

“One of the challenges with IV sedation is that we do not have a way to measure the level of sedatives in the blood,” explains Dr. Slessarev. “Critically ill patients that are sedated can sometimes develop issues with the kidney and liver, which are both important in eliminating the sedatives from the blood stream.”

Through this novel collaborative research, the team is now looking at the potential benefits of inhaled sedation in paediatric patients.

“Inhaled sedatives are an alternative to currently used IV sedatives, and they may reduce delirium and accelerate brain recovery. Inhaled sedatives are used safely every day in operating rooms, widely available and inexpensive,” explains Dr. Jerath. “In contrast to IV sedatives, they do not accumulate in the body, are rapidly eliminated via the lungs, promote faster awakening and discharge from a ventilator, and reduce inflammation – which may be a contributing factor to delirium.”

Enrollment for the ABOVE trial is beginning at Children’s Hospital at LHSC and SickKids. The pilot study will enroll 60 critically ill paediatric patients who will be randomized into two groups; one group will receive inhaled sedation while the other will get standard IV sedation. Once the pilot phase of the trial is complete, the team hopes to expand this trial across the country with more paediatric intensive care units (ICUs) joining the larger trial.

“The field of critical care has made significant strides in life-saving technologies and therapies in recent years, but now we are focused on finding ways to ensure our patients continue to do well after leaving the hospital,” says Dr. Nicole McKinnon, Critical Care Physician and lead investigator at SickKids and a Scientist Track Investigator at SickKids Research Insitute. “This trial is a first step in better understanding the effects of sedative and pain medications on children’s longer-term neurocognitive development. Our research will be key to providing critically ill children with the greatest chance to flourish at home.”

“This has the potential to change how critically ill children are cared for in paediatric ICUs across Canada and the world,” adds Dr. Ganesan. “We hope that inhaled sedation makes a difference in children’s long-term functional outcomes, so they can thrive and achieve their full potential.” 

The ABOVE Trial recently received funding through a Canadian Institute for Health Research (CIHR) grant.

About Sunnybrook Research Institute: Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto. With well-established programs in basic and applied sciences which span across three scientific platforms and ten clinical programs, SRI is developing innovations in care for the more than 1.3 million patients the hospital cares for annually. To learn more, visit www.sunnybrook.ca/research

About The Hospital for Sick Children: The Hospital for Sick Children (SickKids) is recognized as one of the world’s foremost paediatric health-care institutions and is Canada’s leading centre dedicated to advancing children’s health through the integration of patient care, research and education. Founded in 1875 and affiliated with the University of Toronto, SickKids is one of Canada’s most research-intensive hospitals and has generated discoveries that have helped children globally. Its mission is to provide the best in complex and specialized family-centred care; pioneer scientific and clinical advancements; share expertise; foster an academic environment that nurtures health-care professionals; and champion an accessible, comprehensive and sustainable child health system. SickKids is a founding member of Kids Health Alliance, a network of partners working to create a high quality, consistent and coordinated approach to paediatric health care that is centred around children, youth and their families. SickKids is proud of its vision for Healthier Children. A Better World.